In 2008, we funded the first translational myeloma research centre at the Institute of Cancer Research (ICR) in London.
Although treatment for Multiple Myeloma has improved over the last 10 years it still remains an incurable disease. Current treatments can have an adverse effect on patients and there is a need to develop more effective and kinder treatments for Multiple Myeloma patients.
Recent studies have shown that Multiple Myeloma is not a single cancer but rather a group of diseases with Multiple Myeloma cells carrying different gene mutations. These genetic differences can have a profound effect on patient outcomes. Discovering these genetic defects and understanding how they affect tumours means patients could receive treatments tailored to them. It will also enable the development of new drugs and provide data to support drug access approvals.
This programme has been developed as a portfolio of inter-related projects to: gain a better understanding of how myeloma develops, progresses, and how it can be better treated. The research capitalises on the donation of bone marrow material that patients have provided over several years as part of trials and exploits state of the art genome analyses coupled with intelligent drug design.
£432,459 for year 1 of 5-year project